Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis

Cecilia Danielson1,2*, Gabriele Lileikyte1,2*, Wouter Ouwerkerk PhD1,3, Carolyn S.P. Lam MBBS, PhD1,4,5, David Erlinge MD, PhD2 and Tiew-Hwa Katherine Teng MPH, PhD1,4,6

1National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore; 2Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, SE-221 85, Sweden; 3Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands; 4Duke-NUS Medical School, Singapore, Singapore; 5Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and 6School of Allied Health, University of Western Australia, Perth, Australia

Abstract

Aims Recent studies have suggested potential sex differences in treatment response to pharmacological therapies in heart failure (HF). We performed a systematic review and meta-analysis of studies comparing treatment effects between men and women with HF and reduced ejection fraction (HFrEF) using established guideline-directed medical therapy and other emerging pharmacological treatments.

Methods and results Systematic search was performed on PubMed, Embase, and Cochrane Library for randomized controlled trials published in 1990–2021. Outcomes were all-cause mortality and combined outcome of all-cause mortality and/or hospitalization for HF. Of 618 articles identified, 25 articles and 100,213 patients (mean age 62 ± 1.7 years, women 23.1%, mean left ventricular ejection fraction 26.6 ± 1.3%) were included in the systematic review and meta-analysis. For the outcome of all-cause mortality, there was no evidence of treatment heterogeneity by sex for renin-angiotensin system inhibitors (RASI) [hazard ratio (HR) 0.86 (95% confidence interval 0.75–0.99) in men; HR 0.97 (0.77–1.23) in women; Pinteraction = 0.288], or for beta-blockers (BB) [HR 0.71 (0.59–0.86) in men; HR 0.87 (0.73–1.03) in women; Pinteraction = 0.345]. Similarly, for the composite outcome of death or HF hospitalization, there was no evidence of treatment heterogeneity by sex for RASI [HR 0.84 (0.77–0.93) in men; HR 0.94 (0.81–1.08) in women; Pinteraction = 0.210] or BB [HR 0.76 (0.64–0.90) in men; HR 0.72 (0.60–0.86) in women; Pinteraction = 0.650]. Results for mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) from previously published meta-analyses were included in the review. For the combined outcome of cardiovascular death or HF hospitalization, no significant interaction for sex was observed for MRA (Pinteraction = 0.78) or SGLT2i (Pinteraction = 0.37). Results for emerging pharmacological treatments, such as soluble guanylate cyclase stimulators and cardiac myosin activators, were included in the review and showed consistent treatment effects between men and women.

Conclusions Our meta-analysis showed no differences between sex in treatment effect for BB and RASI. Review on previously published trials for MRA, SGLT2i, and emerging therapies presented consistent treatment effects between men and women.

Keywords Heart failure with reduced ejection fraction; Sex differences; Pharmacology; Guideline-directed medical therapy

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Foundational treatments recommended for heart failure (HF) with reduced ejection fraction (HFrEF) comprise of renin-angiotensin system inhibitors (RASi), which include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB); angiotensin receptor-neprilysin inhibitors (ARNi); beta-blockers (BB); mineralocorticoid receptor antagonists (MRA); ivabradine; and sodium-glucose cotransporter-2 inhibitors (SGLT2i).1-2 Emerging novel agents, such as soluble guanylate cyclase (sGC) stimulators and cardiac myosin activators, showed promising results in HFrEF.3,4 There is a growing body of literature suggesting sex dimorphism in the pathophysiology and varying pharmacological response to cardiovascular drugs, including in the setting of HF.5-7

Aim

We performed a systematic review and meta-analysis comparing pharmacological therapy effects for mortality and hospitalization outcomes among men and women with HFrEF.

Methods

A systematic search was performed on PubMed, Embase, and Cochrane Library for randomized controlled trials published between 1990 and February 2021, with subject headings HFrEF, pharmacological therapy, and sex.8 Treatments included RASI, BB, MRA, ARNi, ivabradine, SGLT2i, sGC stimulators, and cardiac myosin activators. Supporting information Figure S1 shows the full search strategy. Inclusion criteria were (i) patients aged ≥18 years with HFrEF (EF < 40%); (ii) ≥1 of the pharmacological therapies applied; (iii) comparison of treatment effect between sex with hazard ratio (HR), odds ratio or relative risk; and (iv) mortality and/or hospitalization outcome.

The abstracts extracted were screened by two investigators (C.D. & G.L.) independently. In case of disagreement, arbitration from a third independent reviewer (T.H.K.T. & W.O.) was sought. Full-text articles included by consensus were eligibility-reviewed by the third reviewer. The risk-of-bias analysis was performed according to Cochrane Consumers & Communication review group: Study quality guide.9 Reporting bias was assessed with funnel plots and formally tested using the Egger test to assess funnel plot symmetry.10 When this was found nonsignificant (P > 0.05), we considered the risk of reporting bias as 'low'.

Chosen outcomes were all-cause mortality or all-cause mortality and/or HF hospitalization (combined outcome). Z scores for outcomes in sex were analysed using combined fixed-and-random-effects meta-analysis with R software. The results were presented as HR comparing men to women with 95% confidence interval (CI) that the treatment is better than comparison. Heterogeneity was assessed using Higgins I² statistics.11 Sensitivity analyses were performed for RASI and BB, excluding studies with unique methodological features that differ from the rest of the included trials. Excluded studies with reasoning and results for the sensitivity analyses are presented in the supporting information.

To assess the influence of background therapy on effect size, we performed a meta-regression using publication year as a predictor. Meta-regression model added studies in ascending order according to publication year, that is, increasing percentage of patients on background therapy in accordance with modern GDMT (Table S7). Ethics approval is not required for a systematic review and meta-analysis.

Results

Systematic search identified a total of 618 articles after exclusion of duplicates. After screening, 25 randomized controlled trials with 100 213 patients (mean age 62 ± 1.7 years, women 23.1%, mean LVEF 26.6 ± 1.3%) were included (Table 2). Trial outcomes, interventions, and sample sizes are presented in Table 2. All studies were assessed to have a low risk of bias (Table S2). Assessment of funnel plots is presented in Figure S2. There was no evidence of systematic reporting bias for the majority of outcomes, that is, RASI-mortality (Egger P = 0.621), RASI-combined (P = 0.586), or BB-combined (P = 0.487). Reporting bias was noted for BB-mortality outcome (P < 0.001, Table S2).

For all-cause mortality in patients using RASI, the overall HR was 0.86 (95% CI 0.73–1.01), with no significant interaction of sex ([HR 0.86 (0.75–0.99) in men; HR 0.97 (0.77–1.23) in women]; Pinteraction = 0.288, Figure 1A). Heterogeneity (I²) among studies was 59.1%. Publication year accounted for up to 21.2% heterogeneity among effect sizes (Table S4 and Figure S4). For the composite outcome of all-cause mortality and/or HF hospitalization, the overall HR was 0.84 (0.76–0.93), with no significant difference between sex ([HR 0.84 (0.77–0.93) in men; HR 0.94 (0.81–1.08) in women], Pinteraction = 0.210, Figure 1B). I² was 66.6%, with publication year explaining 7.6% of the difference in effect size (Table S5 and Figure S5).

For BB, a consistent reduction in risk was observed in men [HR 0.71 (0.59–0.86)] and women [HR 0.87 (0.73–1.03)] for all-cause mortality, with overall HR 0.72 (0.60–0.85), Pinteraction = 0.345, Figure 1C). Heterogeneity (I²) was 63.7%, with no heterogeneity accounted to publication year (Table S6 and Figure S6). For the composite outcome, a significant risk reduction in both men [HR 0.76 (0.64–0.90)] and women [HR 0.72 (0.60–0.86)] treated with BB was observed, with

ESC Heart Failure 2022; 9: 2753–2761
DOI: 10.1002/ehf2.13974
In sensitivity analyses considering BB and RASi with corresponding outcomes, results were comparable. Results remained similar for RASi outcomes, but excluding trials from BB outcomes resulted in numerically more beneficial results for men and women (Table S3 and Figure S3).

Two studies analysing the effect of SGLT2i on cardiovascular death or HF hospitalization among patients with HFrEF were included.12,13 DAPA-HF and EMPEROR-Reduced trials were previously meta-analysed, with a significant risk reduction in both men [HR 0.76 (0.68–0.85)] and women [HR 0.68 (0.56–0.84)], $P_{interaction} = 0.37$.14

We found three trials examining MRA effect (RALES, EPHE-SUS, & EMPHASIS-HF).15–17 RALES and EMPHASIS-HF were meta-analysed at individual patient-level previously, with a consistent treatment effect in men [HR 0.65 (0.58–0.74)] and women [HR 0.67 (0.54–0.83)] on the risk of cardiovascular death or HF hospitalization ($P_{interaction} = 0.78$).18

The data collected for other included treatments was not sufficient for meta-analyses. ARNi, presented in PARADIGM-HF, was shown to be superior to ACEi in reducing cardiovascular mortality and HF hospitalization in both men and women ([HR 0.80 (0.72–0.90); HR 0.77 (0.62–0.95), respectively]; $P_{interaction} = 0.630$).19 Trials examining ivabradine presented no treatment interaction between sex in SHIFT ($P_{interaction} = 0.103$) and BEAUTIFUL ($P_{interaction} = 0.226$).20,21 Recent studies VICTORIA-HF (on sGC stimulator) and GALACTIC-HF (on cardiac myosin activator) showed consistent favourable results in men and women for the composite outcome of cardiovascular mortality or HF hospitalization.3,4

Overall HR 0.76 (0.64–0.90), $P_{interaction} = 0.650$, $I^2 = 0$%, Figure 1D).

Table 1 Mean baseline characteristics of a pooled and averaged study population

| Region         | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------|-----------------------|-----------------|------------------------|------------|
| Asia           | 0                     | 0               |                        |            |
| Europe         | 3                     | 12              |                        |            |
| North America  | 3                     | 12              |                        |            |
| South America  | 0                     | 0               |                        |            |
| Africa         | 0                     | 0               |                        |            |
| International  | 20                    | 77              | 100 213                |            |

| Medication type                  | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------------------------|-----------------------|-----------------|------------------------|------------|
| Beta-blockers                    | 5                     | 22              |                        |            |
| ACEi                             | 5                     | 22              |                        |            |
| ARB                              | 3                     | 13              |                        |            |
| MRA                              | 3                     | 13              |                        |            |
| ARNi                             | 1                     | 4               |                        |            |
| SGLT2 inhibitors                 | 2                     | 9               |                        |            |
| Ivabradine                       | 2                     | 9               |                        |            |
| Cardiac myosin activators        | 1                     | 4               |                        |            |
| sGC stimulators                  | 1                     | 4               |                        |            |

| Characteristics                  | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------------------------|-----------------------|-----------------|------------------------|------------|
| Women                            | 23.1                  | 23 149          |                        |            |
| Ischaemic heart disease          | 59.6                  | 59 727          |                        |            |
| LVEF                             |                        |                 | 26.6 ± 1.3             |            |
| Age                              |                       |                 | 62.14 ± 1.7            |            |

| Control variable                 | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------------------------|-----------------------|-----------------|------------------------|------------|
| Placebo                          | 16                    | 70              |                        |            |
| Another drug                      | 5                     | 22              |                        |            |
| Standard care                     | 2                     | 9               |                        |            |

| Comorbidities                    | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------------------------|-----------------------|-----------------|------------------------|------------|
| Coronary artery disease          | 37.9                  | 37 981          |                        |            |
| Hypertension                     | 54.3                  | 54 416          |                        |            |
| Chronic kidney disease           | 33.3                  | 33 371          |                        |            |
| Diabetes mellitus                | 30.8                  | 30 866          |                        |            |
| Anaemia                          | 21.2                  | 21 245          |                        |            |
| Atrial fibrillation              | 29.4                  | 29 463          |                        |            |

| Risk factors                     | Number of studies (n) | Percentages (%) | Number of patients (n) | Mean (±SD) |
|----------------------------------|-----------------------|-----------------|------------------------|------------|
| Smoking                          | 35.2                  | 35 275          | 122.3 ± 2.6            |            |
| Systolic blood pressure          |                       |                 |                        |            |
| Diastolic blood pressure         |                       |                 | 75.5 ± 1.9             |            |
| Heart rate                       |                       |                 | 76.2 ± 1.9             |            |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; sCG, soluble guanylate cyclase; SGLT2, sodium-glucose cotransporter 2.
Table 2  Outcomes, interventions, and sample sizes for the corresponding trials included in the systematic review and meta-analysis

| Trial name          | Medication       | Sample size | Percentage of women | HR (95% CI) men | HR (95% CI) women | Outcome                                      | Background therapy (% of patients) |
|---------------------|------------------|-------------|---------------------|-----------------|-------------------|----------------------------------------------|----------------------------------|
| AIRE                | ACEi             | 2006        | 27.0%               | 0.75 (0.58–0.98) | 0.70 (0.50–0.98)  | All-cause mortality                          | BB—22.0%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi (intervention) NA—NA              |
|                     |                  |             |                     |                 |                   |                                              | MRA—NA—NA                         |
| ATLAS               | ACEi             | 3164        | 20.2%               | 0.87 (0.78–1.00) | 0.90 (0.83–0.97)  | All-cause mortality                          | BB—11.0%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—88.0% (ACEi) MRA—NA              |
|                     |                  |             |                     |                 |                   | Combined outcome                              | MRA—37.4%                        |
| ATLAS               | Aliskiren vs. ACEi | 4676        | 21.2%               | 0.95 (0.85–1.06) | 1.00 (0.88–1.13)  | Combined outcome                              | BB—91.6%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi (comparison) MRA—88.0% (ACEi)    |
|                     |                  |             |                     |                 |                   | All-cause mortality                           |                                  |
| BEAUTIFUL           | Ivabradine       | 12 473      | 17.0%               | 0.98 (0.75–1.15) | 1.14 (0.80–1.50)  | CV death, MI, or HF hospitalization           | BB—87.0%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—90.0% MRA—NA                    |
|                     |                  |             |                     |                 |                   |                                              | BB (tested) MRA—6.5% (ARB)            |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| BEST                | BB               | 2708        | 21.0%               | 0.90 (0.70–1.03) | 0.90 (0.60–1.20)  | All-cause mortality                          | BB—4.0%                         |
|                     |                  |             |                     |                 |                   |                                              | RASi—91.5% (ACEi), 6.5% (ARB) MRA—3.5% |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| CHARM               | ARB              | 4576        | 25.9%               | 0.82 (0.74–0.90) | 0.80 (0.68–0.98)  | CV death or HF hospitalization               | BB—55.1%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—55.7% (ACEi) MRA—20.1%           |
|                     |                  |             |                     |                 |                   |                                              |                                  |
| CIBIS III           | BB followed by ACEi | 1010       | 34.1%               | 0.80 (0.65–1.20) | 0.85 (0.65–1.45)  | Combined outcome                              | BB (intervention) RASi—13.3%     |
|                     |                  |             |                     |                 |                   |                                              |                                  |
| COMET               | BB               | 3029        | 21.0%               | 0.80 (0.70–0.91) | 0.97 (0.73–1.27)  | All-cause mortality                          | BB—4.0%                         |
|                     |                  |             |                     |                 |                   |                                              | RASi—91.5% (ACEi), 6.5% (ARB) MRA—11.0% |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| COPERNICUS          | BB               | 2289        | 21.0%               | 0.65 (0.52–0.80) | 0.65 (0.40–1.10)  | All-cause mortality                          | BB—96.1%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—56.1% (ACEi), 27.6% (ARB) MRA—71.4% |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| DAPA-HF             | SGLT2i           | 4744        | 23.8%               | 0.73 (0.63–0.85) | 0.79 (0.59–1.06)  | CV death or HF hospitalization               | BB—94.7%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—69.7% MRA—71.4%                |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| EMPEROR-Reduced     | SGLT2i           | 3730        | 23.5%               | 0.80 (0.68–0.93) | 0.59 (0.44–0.80)  | CV death or HF hospitalization               | BB—86.8%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—77.6% on ACEi, 19.3% on ARB MRA—71.4% |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| EMPHASIS-HF         | MRA              | 2743        | 22.7%               | 0.75 (0.65–0.85) | 0.60 (0.40–0.85)  | CV death or HF hospitalization               | BB—75.0%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—86.5% MRA (tested)              |
|                     |                  |             |                     |                 |                   |                                              |                                 |
| EPHESUS             | MRA              | 6632        | 28.0%               | 0.85 (0.75–1.10) | 0.80 (0.60–0.95)  | All-cause mortality                          | BB—94.3%                        |
|                     |                  |             |                     |                 |                   |                                              | RASi—87.0% (including ARNi) MRA—77.7%   |
| GALACTIC-HF         | Cardiac myosin activator | 8232 | 21.2% | 21.3% | 0.92 (0.85–0.99) | 0.95 (0.81–1.12) | CV death or HF hospitalization | BB—75.0% | 
|                     |                  |             |                     |                 |                   |                                              | RASi—86.5% MRA (tested)              |
|                     |                  |             |                     |                 |                   |                                              |                                 |

(Continues)
| Trial name | Medication | Sample size | Percentage of women | HR (95% CI) men | HR (95% CI) women | Outcome | Background therapy (% of patients) |
|-----------|------------|-------------|---------------------|-----------------|------------------|---------|-----------------------------------|
| HEAAL     | ARB        | 3846        | 30.0%               | 0.86 (0.77–0.96) | 1.02 (0.85–1.23) | Combined outcome | BB—72%, RASi (intervention) MRA—38.0%, BB—NA RASi (tested) MRA—NA BB (intervention) RASi—95.5%, MRA—NA |
| High Enalapril Dose Study | ACEi | 248        | 19.4%               | 1.09 (0.58–2.02) | 0.73 (0.12–4.38) | All-cause mortality | BB—93.0%, RASi (comparison) MRA—55.6%, BB—10.5% RASi—94.5% (ACEi) MRA (intervention) BB—89.5% RASi—78.5% (ACEi), 14.0% (ARB) MRA—60.0% BB—7.7%, RASi (intervention) MRA—NA |
| MERIT-HF  | BB         | 3991        | 23.0%               | 0.60 (0.50–0.75) | 0.90 (0.58–1.50) | All-cause mortality | BB—95.5%, RASi—95.0%, MRA—94.5% (ACEi) MRA—95.5% BB—NA RASi—95.5%, MRA—NA |
| PARADIGM-HF | ARNi vs. ACEi | 8399      | 21.0%               | 0.80 (0.72–0.90) | 0.77 (0.62–0.95) | Combined outcome | BB—93.0%, RASi (tested) MRA—95.5% |
| RALES     | MRA        | 1663        | 27.0%               | 0.70 (0.60–0.85) | 0.71 (0.52–0.98) | All-cause mortality | BB—89.5% RASi—78.5% (ACEi), 14.0% (ARB) MRA—60.0% BB—7.7%, RASi (intervention) MRA—NA |
| SHIFT     | Ivabradine | 6505        | 21.7%               | 0.84 (0.76–0.94) | 0.74 (0.60–0.91) | CV death or HF hospitalization | BB—89.5% RASi—78.5% (ACEi), 14.0% (ARB) MRA—60.0% BB—7.7%, RASi (intervention) MRA—NA |
| SOLVD     | ACEi       | 2569        | 19.0%               | 0.70 (0.62–0.78) | 0.94 (0.74–1.20) | Combined outcome | BB—95.0% (ACEi) MRA—94.5% (ACEi) MRA—95.5% |
| TRACE     | ACEi       | 1749        | 28.0%               | 0.74 (0.62–0.89) | 0.90 (0.69–1.18) | All-cause mortality | BB—16%, RASi (intervention) MRA—NA BB—95.0% (ACEi) MRA—95.5% BB—NA BB—92.7% (ACEi) MRA—NA |
| U.S. Carvedilol Heart Failure Study | BB | 1094        | 23.0%               | 0.41 (0.22–0.80) | 0.23 (0.07–0.69) | All-cause mortality | BB—95.0% (ACEi) MRA—95.5% BB—95.0% (ACEi) MRA—95.5% |
| Val-HeFT  | ARB and ACEi | 3034      | 19.6%               | 0.83 (0.73–0.95) | 0.75 (0.56–1.00) | Morbidity | BB—34.9%, RASi—92.7% (ACEi) MRA—NA BB—93.1%, RASi—73.4% MRA—70.3% |
| VICTORIA  | sGC stimulator | 5050      | 24.0%               | 0.90 (0.81–1.00) | 0.88 (0.73–1.08) | CV death or HF hospitalization | BB—34.9%, RASi—92.7% (ACEi) MRA—NA |

ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; CI, confidence interval; CV, cardiovascular; HF, heart failure; HR – hazard ratio; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonists; NA, non-assessed; sGC, soluble guanylate cyclase; SGLT2i, sodium-glucose cotransporter-2 inhibitors.

Combined outcome refers to all-cause mortality and/or hospitalization for heart failure.

Background therapy measurements for each study were defined as mean values for intervention and comparison.
Figure 1  Meta-analysis of renin-angiotensin system inhibitors (RASI) and beta-blockers (BB) effects in heart failure with reduced ejection fraction treatment in men vs. women presented as hazard ratios with 95% confidence intervals. RASI effect was evaluated for the outcome of all-cause mortality (A) and combined outcome of all-cause mortality and HF hospitalization (B) in men and women. BB effect was respectively evaluated for all-cause mortality (C) and combined outcome of all-cause mortality and HF hospitalization (D). BB, beta-blockers; CI, confidence interval; HR, hazard ratio; RASI, renin-angiotensin system inhibitors; RE, random effects.

(A) Mortality outcome RASI

| Study                | Hazard Ratio (95% CI) |
|----------------------|-----------------------|
| High Enalapril Dose Study | 1.09 [0.95, 1.24] |
| ATMOSPHERE           | 1.02 [0.88, 1.18] |
| TRACE                | 0.74 [0.62, 0.89] |
| ATLAS                | 0.87 [0.76, 1.00] |
| AIRE                 | 0.70 [0.57, 0.89] |

RE Model: 0.85 [0.75, 0.96]

Observed Outcome

(B) Combined outcome RASI

| Study                | Hazard Ratio (95% CI) |
|----------------------|-----------------------|
| SOLVO                | 0.70 [0.63, 0.78] |
| ATMOSPHERE           | 0.95 [0.85, 1.06] |
| Valsartan            | 0.83 [0.73, 0.95] |
| HEAL                | 0.86 [0.77, 0.96] |
| CIBIS II             | 0.80 [0.53, 1.20] |
| AIRE                 | 0.90 [0.34, 0.97] |

RE Model: 0.94 [0.77, 0.92]

Observed Outcome

(C) Mortality outcome β-blocker

| Study                | Hazard Ratio (95% CI) |
|----------------------|-----------------------|
| COMET                | 0.80 [0.70, 0.91] |
| COPERNICUS           | 0.65 [0.53, 0.80] |
| U.S. Cardiologist HF Study | 0.41 [0.21, 0.80] |
| BEST                 | 0.90 [0.79, 1.00] |
| MERIT-HF             | 0.60 [0.48, 0.70] |

RE Model: 0.73 [0.55, 0.98]

Observed Outcome

(D) Combined outcome β-blocker

| Study                | Hazard Ratio (95% CI) |
|----------------------|-----------------------|
| CIBIS II             | 0.90 [0.53, 1.20] |
| COPERNICUS           | 0.73 [0.53, 0.90] |

RE Model: 0.76 [0.54, 0.96]

Observed Outcome
Sex differences in efficacy of pharmacological therapies in HFrEF

Discussion and conclusions

Our meta-analysis showed no sex differences in treatment effect of BB and RASi among patients with HFrEF. Previous systematic reviews on MRA, SGLT2i, and emerging pharmacological treatments presented consistent treatment effects between sex.

For this meta-analysis, ACEi and ARB treatments were analysed together as RASI. However, ARB is no longer recommended as first-option medication for patients with chronic HFrEF, partly because trials examining ARB could not demonstrate reduced all-cause mortality.\(^{1}\) This, in turn, negatively affects the results for the combined analysis of ACEi and ARB in both sex, as illustrated by the differentiating results compared with an earlier meta-analysis on ACEi.\(^{22}\)

Differences in pharmacodynamics and pharmacokinetics between men and women are a familiar phenomenon, but the exact mechanisms are still to be investigated for all HFrEF therapy.\(^{23,24}\) These variations between sex could potentially influence the efficacy of HFrEF drugs, although its statistical relevance is unknown, likely due to a marginalised presentation of women in clinical trials.\(^{25}\) Results in smaller trials are therefore likely to be affected by datasets for women not being large enough to give statistically powered information, which calls for bigger analyses or pooling of data for evaluation of therapy between sex. For example, GALACTIC-HF, a recent trial on a cardiac myosin activator, included a large population and therefore a considerable number of women for a statistically significant evaluation.\(^{3}\) Moreover, a survival benefit in women is most likely to present if the treatment is clearly superior to the standard of care, as seen in PARADIGM-HF where a significant effect of ARNi was observed in women although they only constituted 21.8% of the population.\(^{19}\)

This review underscores the under-representation of women in clinical trials of HF. While women represent approximately 40% of the HFrEF population, the total HF population is believed to consist >50% of women.\(^{24,26}\) Yet only 23.1% of the patients included in this meta-analysis were women, a percentage consistent in trials involving patients with HFrEF.\(^{27}\) Although this meta-analysis showed no sex differences in treatment effect, a trend of inconsistency between the HR estimates is noticeable, with women presenting neutral effects in response to BB and RASi as compared with consistently favourable outcomes in men. While reasons for this could be multifactorial, a prominent cause is selection bias due to low percentage of women included in HFrEF trials. Therefore, a more balanced recruitment of both sex into future trials on pharmacotherapy is warranted. One could expect that if the inclusion by sex was proportional, the estimate for women would regress around that of men, a trend seen in HFrEF trials.\(^{28}\) A targeted approach directed at eligible women, coupled with an educational programme on the benefits of the study drug, might increase the participation of women in HFrEF trials.

This study includes several potential limitations. Included studies did not differentiate between symptomatic and asymptomatic patients with HFrEF, which is suggested to affect the long-term outcomes.\(^{29}\) Dose-dependent effect differences between sex could not be assessed due to limited data in included trials, as dose-dependent differences between sex have been reported previously.\(^{7}\) Finally, analysis was not performed at individual patient-level, which limited analyses to specific outcomes.

In conclusion, our meta-analysis showed no sex differences in response to BB and RASi in the management of chronic HFrEF. Previous systematic reviews on MRA, SGLT2i, and emerging pharmacological treatment presented consistent treatment effects between sex.

Acknowledgements

The authors acknowledge Maria Björklund for the help with the literary search.

Conflict of interest

The authors declared no conflict of interest relevant to the present work. C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd and Corpus; and serves as co-founder & non-executive director of eKo.ai.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. A) Flow chart for inclusion of articles. B) Search strategy for PubMed. Performed on 11\(^{th}\) February 2021. Identical searches were performed on Embase and The Cochrane Library.

Figure S2. a) Forest and residual funnel plot with adjusted HRs with sex as a modifier showing the risk of bias for mortal-
ity outcome in patients using Renin Angiotensin System inhibitors (RASi). Analysed according to random-and-fixed-effects model using R package metaphor.

Figure S2. b). Forest and residual funnel plot with adjusted HRs with sex as a modifier showing the risk of bias for combined outcome (all-cause mortality and/or HF-hospitalisation) in patients using Renin Angiotensin System inhibitors (RASi). Analysed according to random-and-fixed-effects model using R package metaphor.

Figure S2. c). Forest and residual funnel plot with adjusted HRs with sex as a modifier showing the risk of bias for mortality outcome in patients using beta-blockers (BB). Analysed according to random-and-fixed-effects model using R package metaphor.

Figure S2. d). Forest and residual funnel plot with adjusted HRs with sex as a modifier showing the risk of bias for combined outcome (all-cause mortality and/or HF-hospitalisation) in patients using beta-blockers (BB). Analysed according to random-and-fixed-effects model using R package metaphor.

Figure S3. Forest plots for sensitivity analysis in men and women. Performed using R-software, mixed-effect modelling.

Figure S4. Forest and funnel plots for RASi all-cause mortality according to publication year in ascending order. Analysed using meta-regression.

Figure S5. Forest and funnel plots for RASi combined outcome according to publication year in ascending order. Analysed using meta-regression.

Figure S6. Forest and funnel plots for BB all-cause mortality according to publication year in ascending order. Analysed using meta-regression.

References

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Bumpach A, Bohm M, Burri H, Butler J, Celutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJ, Mebazaa A, Mindham R, Milione C, Francesco Piepoli M, Price M, McMurray J, Mebazaa A, Mindham R, Milione C, Francesco Piepoli M, Price M, Reynolds R, Rich S, Ruschitzka F, Kathrine Skibelund A, ESCScientificDocumentGroup. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42: 3599–3726.

2. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motivala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77: 772–810.

3. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfran DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E, Parkhomenko A, Ponikowski P, Ramiess FRA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Zielinski J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJ, Mebazaa A, Mindham R, Milione C, Francesco Piepoli M, Price M, McMurray J, Mebazaa A, Mindham R, Milione C, Francesco Piepoli M, Price M, Reynolds R, Rich S, Ruschitzka F, Kathrine Skibelund A, ESCScientificDocumentGroup. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42: 3599–3726.

4. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382: 1883–1893.

5. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009; 80: 1254–1258.

6. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009; 48: 143–157.

7. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, Voors AA, Richards AM, Anand I, Hung CL, Ling LH, Liew HB, Narasimhan C, Ngarmukos T, Park SW, Reyes E, Siswanto BB, Shimizu W, Zhang S. Identifying optimal doses of heart failure medications in men compared with women: a prospective study. ESC Heart Failure. 2022; 9: 2753–2761. DOI: 10.1002/ehf2.13974
Sex differences in efficacy of pharmacological therapies in HFrEF

1. Packer M, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofrad AP, Pfarr E, Jamal W, Packer M. SGTL2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. *Lancet*. 2020; 396: 819–829.

2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. *JAMA*. 1995; 273: 1450–1456.

3. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kasci JK, Ceconi C, Drexel H, Kjeldsen S, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S. Gender differences in the effects of cardiovascular drugs. *Eur Heart J Cardiovasc Pharmacother*. 2017; 3: 163–182.

4. Farrero M, Bellumkonda L, Gómez Otero I, Díaz Molina B. Sex and heart failure treatment prescription and adherence. *Frontiers in Cardiovascular Medicine*. 2021; 8: 320.

5. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. *Eur Heart J*. 2005; 26: 1585–1595.

6. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern Med*. 2015; 175: 996–1004.

7. Mentzer G, Hsich EM. Heart failure with reduced ejection fraction in women: epidemiology, outcomes, and treatment. *Heart Fail Clin*. 2019; 15: 19–27.

8. Sotomi Y, Hikosio S, Nakatani D, Mizuno H, Okada K, Dohi T, Kitamura T, Sunaga A, Kida H, Oeun B, Sato T, Komukai S, Tamaki S, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Yasumura Y, Yamada T, Sakata Y, the PURSUIT-HFpEF Investigators. Sex differences in heart failure with preserved ejection fraction. *J Am Heart Assoc*. 2021; 10: e018574.

9. Reed BN, Sueta CA. Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction? *Curr Cardiol Rev*. 2015; 11: 18–22.